Clay Siegall began his career in research as a Senior Research Investigator at the Bristol – Myers Squibb Pharmaceutical Research Institute. Dr. Siegall was promoted as Principal Scientist before he bcame a Fellow and Biotechnology Fellow at the National Cancer Institute. Where he began to help launch Seattle Genetics.
Clay Siegall earned his Ph.D. in Gentics and ever since then has made a impact on cancer. Dr. Siegall works to lead the company to great advancements in cancer and ground breaking therapies for cancer patients commuted to important research and research developments to help cancer patients. Dr. Siegall helped Seattle Genetics develop the first antibody drug conjugated including ADCETRIS FDA approved in 2011. ADCETRIS is helping cancer patients in 60 countries. Dr. Siegall known as a leader in new cancer therapies and helps more by fundraisingfor Seattle Genetics raising $1.2 billion.
In result of Seattle Genetics to thrive in advancements in cancer treatments with innovative technology. With the University of Maryland Alumnus of the year for Computer, Math and Natural Science. Dr. Siegall is a very intelligent man with a passion to help others how humbling. Dr. Siegall is ground breaking intelligence to help cancer patients. Also named Paciffic Northwest Ernst and Young Entrepreneur of the year with his scientific achievements. Holding 15 patents with 70 scientific articles published his in depth knowledge in science and medical.
A mentor to young students all around Dr. Siegall inspires more than just his patients. Dr. Siegall strives to help others always putting them first. An honorable man that has knowledge to help others.
Dr. Siegall built Seattle Venice on a foundation of scientific innovation, rigourous research and drug development. Dr. Siegall has a passion for helping others. Clay Siegall is responsible for pioneering alternative drugs for cancer and other deblilitatis genectics disorders. His goal of medication to have a positive impact of those suffering with cancer. Dr. Siegalls role is to create innovative antibody based therapies. To help suffering cancer patients with out nasty side effects